Accelerating Through Consolidation: Why PE-Backed Buy‑and‑Builds Are Transforming Medtech & Pharma Talent Strategy

At RMG, we’ve worked with dozens of Medtech and Pharma businesses navigating transformative growth.

Lately, one theme dominates our conversations: the rise of private equity‑backed buy‑and‑build strategies. As specialist headhunters in this space, we’re seeing that alongside every deal lies a critical talent challenge—and corresponding opportunity.

1. Why PE Firms Are Doubling Down

• Fragmented markets: With diagnostic labs, niche CDMOs, and medtech platforms spread thin, consolidation offers scale.

• Favourable tailwinds: Rapid regulatory updates, demographic shifts, and personalised medicine developments make this space appealing to PE.

• Value creation: Acquisition multiples and exit multiples rise when platform businesses offer integrated end‑to‑end capabilities—something PE loves.

2. Recruitment at Bolt‑Speed

Deploying a rapid roll‑up is thrilling—but leaves little time to build a resilient team. We’re working with clients who urgently need:

• General Managers accustomed to integrating newly acquired teams

• Commercial leaders who can unify disparate sales channels

• Regulatory & QA heads with multi‑jurisdictional experience

• Financial leaders skilled in post‑deal integration and reporting

These aren’t roles where you can simply plug in industry experience. PE‑backed platforms demand performance under intense scrutiny.

3. Cultural Integration: The Unspoken Risk

Layering three to five different organisational cultures generates friction. We're spotting a growing demand for leaders who can:

• Create one cohesive identity across acquisitions

• Retain key talent during turbulent post‑deal phases

• Drive immediate execution—while preserving employee engagement

That means candidates with integration skills, emotional intelligence, and the ability to cosmopolite a newly formed team.

4. What This Means for Talent

If you've been in the trenches of buy‑and‑build, you’re now a rare commodity. PE investors are no longer just looking for Medtech or Pharma specialists—they want builders: those who can operate in complexity, ambiguity, and scale.

That includes individuals with experience in:

• Rapid post‑deal scale-ups

• Cultural integrations after PE-sponsored acquisitions

• Delivering synergies under tight timelines

Those career milestones—especially when backed by PE governance—are gold dust in today’s market.

5. How RMG Supports

We don’t just match CVs—we bring market insight, candidate vetting, and integration coaching to the table:

• Deep networks in Medtech & Pharma—plus insight into emerging PE platforms

• Tailored assessment frameworks focused on integration capability

• Ongoing support for both client and candidate through critical post-deal phases

Our clients tell us time and again: RMG brings clarity and control when everything is changing fast.

Final Word

PE-backed buy‑and‑build isn’t a passing trend—it’s a structural shift in Medtech & Pharma. For investors, it's a route to scale; for companies, an accelerator; for candidates, a career‑making moment.

At RMG, we’re in the thick of it—connecting growth-minded businesses with the leaders they need to thrive. If you're part of a PE playbook (or thinking of joining one), let’s explore how we can help

---